An observational study in Pneumonia and Type 2 Diabetes Mellitus (T2DM), sponsored by Chung Shan Medical University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Chung Shan Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Pneumonia with a site in Taiwan — 8 open to participants now, 10 under way, 2 of them phase 3. Pneumonia · Taiwan.
Among the 33 studies in Pneumonia with a site in Taiwan, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2026, is one of 11 observational ones, and was the 32nd registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →8 of the 33 studies in Pneumonia with a site in Taiwan are open now. Recruiting first, the newest first:
Far Eastern Memorial Hospital · Sites in Taiwan
Ages 18–90
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 18+
Pfizer · Sites in Taiwan, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Taiwan, United States, Argentina and 16 more countries
Ages 12+
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 50+ · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 71,775 is above the median of 255 across 537 observational studies indexed under Pneumonia.
Median enrollment 202 across the 22 interventional studies, 200 across the 11 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 33 have an industry lead sponsor. The 10 most frequent:
Chung Shan Medical University is the lead sponsor of 126 studies on the registry; 25 are open to participants now.
Chung Shan Medical University has 3 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
6 of the studies in Pneumonia with a site in Taiwan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06605352National Taiwan University Clinical Trial CenterClinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial | 2026-12 |
| NCT07463443Taipei Veterans General Hospital, TaiwanEffectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Study on Knowledge, Attitude and Practice. | 2027-02-24 |
| NCT07103460National Taipei University of Nursing and Health SciencesEssential Oil-Assisted Respiratory Training in Type 2 Diabetic Patients With Lung Infections | 2027-07-25 |
Add all 6 to your calendar (.ics) → With an account.
Among the 33 studies in Pneumonia with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes hospitalized with pneumonia. Time zero is the date of the index pneumonia admission. The study compares patients with evidence of prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission with patients prescribed a GLP-1 receptor agonist alone, an SGLT2 inhibitor alone, or usual care. Usual care includes metformin, sulfonylureas, or DPP-4 inhibitors without either study class. The primary outcome is a composite of all-cause death, invasive mechanical ventilation, or renal replacement therapy within 30 days of admission, with the individual components and 12-month mortality, major adverse cardiovascular events, and major adverse kidney events also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.
Adults will be selected from the TriNetX US Collaborative Network, a distributed database of de-identified electronic health records contributed by participating healthcare organizations across multiple clinical systems and practice settings. The study population consists of adults with type 2 diabetes who were hospitalized with pneumonia and received routine clinical care in this network, identified through diagnosis records, laboratory data, encounter records, and medication prescribing data. Comparator-specific cohorts were defined within this source population according to glucose-lowering prescriptions recorded in the year before the index admission, to evaluate preadmission GLP-1 receptor agonist- and SGLT2 inhibitor-based treatment strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with type 2 diabetes hospitalized with pneumonia who had prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission.
Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for a GLP-1 receptor agonist, and no prescription for an SGLT2 inhibitor, in the year before admission.
Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for an SGLT2 inhibitor, and no prescription for a GLP-1 receptor agonist, in the year before admission.
Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for metformin, a sulfonylurea, or a DPP-4 inhibitor, and no prescription for a GLP-1 receptor agonist or an SGLT2 inhibitor, in the year before admission.
Composite outcome (all-cause mortality, invasive mechanical ventilation, or renal replacement therapy)
Time frame: Within 30 days after the index pneumonia admission
All-cause mortality
Time frame: Within 30 days after the index pneumonia admission
Invasive mechanical ventilation
Time frame: Within 30 days after the index pneumonia admission
Renal replacement therapy
Time frame: Within 30 days after the index pneumonia admission
Composite outcome (all-cause mortality, major adverse cardiovascular events, or major adverse kidney events)
Time frame: Through 12 months after the index pneumonia admission
All-cause mortality
Time frame: Through 12 months after the index pneumonia admission
Major adverse cardiovascular events
Time frame: Through 12 months after the index pneumonia admission
Major adverse kidney events
Time frame: Through 12 months after the index pneumonia admission
Plan to share: No — Individual participant data will not be shared. This retrospective observational study uses de-identified electronic health record data from the TriNetX US Collaborative Network. Access to individual-level data is restricted by data use agreements, institutional policies, and privacy protections. Researchers who meet eligibility requirements may obtain access to similar de-identified data through a TriNetX license or through participating institutions.
Start is estimated for Jul 2026; primary completion for Aug 2026, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chung Shan Medical University →